EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 27 / No 10 (Octobre 2011) Med Sci (Paris), 27 10 (2011) 842-849 References
Free Access
Issue
Med Sci (Paris)
Volume 27, Number 10, Octobre 2011
Page(s) 842 - 849
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20112710012
Published online 21 October 2011
  1. Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992 ; 71 : 1065–1068. [CrossRef] [PubMed] [Google Scholar]
  2. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993 ; 11 : 191–212. [CrossRef] [PubMed] [Google Scholar]
  3. Thompson CB, Lindsten T, Ledbetter JA, et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci USA 1989 ; 86 : 1333–1337. [CrossRef] [Google Scholar]
  4. Linsley PS, Brady W, Grosmaire L, et al. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991 ; 173 : 721–730. [CrossRef] [PubMed] [Google Scholar]
  5. Cerdan C, Martin Y, Courcoul M, et al. CD28 costimulation up-regulates long-term IL-2R beta expression in human T cells through combined transcriptional and post-transcriptional regulation. J Immunol 1995 ; 154 : 1007–1013. [PubMed] [Google Scholar]
  6. Boise LH, Minn AJ, Noel PJ, et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 1995 ; 3 : 87–98. [CrossRef] [PubMed] [Google Scholar]
  7. Tacke M, Hanke G, Hanke T, Hunig T. CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: evidence for functionally distinct forms of CD28. Eur J Immunol 1997 ; 27 : 239–247. [CrossRef] [PubMed] [Google Scholar]
  8. Fraser JD, Irving BA, Crabtree GR, Weiss A. Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science 1991 ; 251 : 313–316. [CrossRef] [PubMed] [Google Scholar]
  9. Granelli-Piperno A, Nolan P. Nuclear transcription factors that bind to elements of the IL-2 promoter. Induction requirements in primary human T cells. J Immunol 1991 ; 147 : 2734–2739. [PubMed] [Google Scholar]
  10. Pages F, Ragueneau M, Rottapel R, et al. Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling. Nature 1994 ; 369 : 327–329. [CrossRef] [PubMed] [Google Scholar]
  11. Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 2009 ; 229 : 12–26. [CrossRef] [PubMed] [Google Scholar]
  12. Sanchez-Lockhart M, Marin E, Graf B, et al. Cutting edge: CD28-mediated transcriptional and posttranscriptional regulation of IL-2 expression are controlled through different signaling pathways. J Immunol 2004 ; 173 : 7120–7124. [PubMed] [Google Scholar]
  13. Miller J, Baker C, Cook K, et al. Two pathways of costimulation through CD28. Immunol Res 2009 ; 13 février (online). [Google Scholar]
  14. Huang J, Lo PF, Zal T, et al. CD28 plays a critical role in the segregation of PKC theta within the immunologic synapse. Proc Natl Acad Sci USA 2002 ; 99 : 9369–9373. [CrossRef] [Google Scholar]
  15. Saito T, Yokosuka T, Hashimoto-Tane A. Dynamic regulation of T cell activation and co-stimulation through TCR-microclusters. FEBS Lett 2010 ; 584 : 4865–4871. [CrossRef] [PubMed] [Google Scholar]
  16. Linsley PS, Golstein P. Lymphocyte activation: T-cell regulation by CTLA-4. Curr Biol 1996 ; 6 : 398–400. [CrossRef] [PubMed] [Google Scholar]
  17. PeachRJ, Bajorath J, Brady W, et al. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. J Exp Med 1994 ; 180 : 2049–2058. [CrossRef] [PubMed] [Google Scholar]
  18. Truneh A, Reddy M, Ryan P, et al. Differential recognition by CD28 of its cognate counter receptors CD80 (B7.1) and B70 (B7.2): analysis by site directed mutagenesis. Mol Immunol 1996 ; 33 : 321–334. [CrossRef] [PubMed] [Google Scholar]
  19. Van der Merwe PA, Bodian DL, Daenke S, et al. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med 1997 ; 185 : 393–403. [CrossRef] [PubMed] [Google Scholar]
  20. Laurent S, Carrega P, Saverino D, et al. CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions. Hum Immunol 2010 ; 71 : 934–941. [CrossRef] [PubMed] [Google Scholar]
  21. Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995 ; 3 : 541–547. [CrossRef] [PubMed] [Google Scholar]
  22. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995 ; 270 : 985–988. [CrossRef] [PubMed] [Google Scholar]
  23. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994 ; 1 : 405–413. [CrossRef] [PubMed] [Google Scholar]
  24. Pedicord VA, Montalvo W, Leiner IM, Allison JP. Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance. Proc Natl Acad Sci USA 2010 ; 108 : 266–271. [CrossRef] [Google Scholar]
  25. Jain N, Nguyen H, Chambers C, Kang J. Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity. Proc Natl Acad Sci USA 2010 ; 107 : 1524–1528. [CrossRef] [Google Scholar]
  26. Ise W, Kohyama M, Nutsch KM, et al. CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms. Nat Immunol 2010 ; 11 : 129–135. [CrossRef] [PubMed] [Google Scholar]
  27. Dustin ML. Insights into function of the immunological synapse from studies with supported planar bilayers. Curr Top Microbiol Immunol 2010 ; 340 : 1–24. [CrossRef] [PubMed] [Google Scholar]
  28. Yokosuka T, Kobayashi W, Sakata-Sogawa K, et al. Spatiotemporal regulation of T cell costimulation by TCR-CD28 microclusters and protein kinase C theta translocation. Immunity 2008 ; 29 : 589–601. [CrossRef] [PubMed] [Google Scholar]
  29. Yokosuka T, Kobayashi W, Takamatsu M, et al. Spatiotemporal basis of CTLA-4 costimulatory molecule-mediated negative regulation of T cell activation. Immunity 2010 ; 33 : 326–339. [CrossRef] [PubMed] [Google Scholar]
  30. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010 ; 107 : 4275–4280. [CrossRef] [Google Scholar]
  31. Van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999 ; 190 : 355–366. [CrossRef] [PubMed] [Google Scholar]
  32. Sharpe AH. Mechanisms of costimulation. Immunol Rev 2009 ; 229 : 5–11. [CrossRef] [PubMed] [Google Scholar]
  33. Olive D. Corécepteurs lymphocytaires. Med Sci (Paris) 2006 ; 22 : 1069–1074. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  34. Watanabe N, Gavrieli M, Sedy JR, et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 2003 ; 4 : 670–679. [CrossRef] [PubMed] [Google Scholar]
  35. Serriari NE, Gondois-Rey F, Guillaume Y, et al. B and T lymphocyte attenuator is highly expressed on CMV-specific T cells during infection and regulates their function. J Immunol 2010 ; 185 : 3140–3148. [CrossRef] [PubMed] [Google Scholar]
  36. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007 ; 12 : 864–872. [CrossRef] [PubMed] [Google Scholar]
  37. Robert C, Matteus C. Anticorps anti-CTLA-4 : une avancée thérapeutique majeure dans le traitement du mélanome métastatique. Med Sci (Paris) 2011 ; 27 : 850–858. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.